Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline pharmacokinetics by CYP1A2 genotype and smoking status in healthy volunteers
ISRCTN68198254Phase 2Completed
- Sponsor
- University of Health Sciences Lahore
- Start
- Jun 2016
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rasagiline in Parkinson's disease (PD) (18 arms), sponsored by University of Health Sciences Lahore. Primary endpoints: Dose of rasagiline required to ensure effective plasma concentrations by CYP1A2 variant and smoking status, Maximum plasma concentration and 5 more. Started Jun 2016; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN68198254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68198254.